Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.82
-$2.71(-4.69%)
At close: 4:00 PM EST
$15.82
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.25M
Market Cap
$934.89M
Enterprise Value-$63.76
Total Cash (Recent Filing)$956.39M
Total Debt (Recent Filing)$21.57M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 11, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,984,352
10 Day Avg. Volume815,157
30 Day Avg. Volume1,249,065
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.33Price Target Upside104.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$32.09M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt-to-equity (~0.02) gives Janux durable financial flexibility to fund clinical programs without heavy interest burden. This buffer reduces near-term insolvency risk, supports R&D cadence, and lengthens runway versus similarly cash-burning peers, aiding multi-quarter program continuity.
Improving Revenue MomentumA 20.9% TTM revenue rebound signals improving top-line traction from collaborations or milestone activity, which can materially reduce net burn if sustained. For a clinical-stage biotech, rising recurring partner payments improve predictability of near-term funding needs and validate program value.
Focused Immuno-oncology PipelineA focused pipeline in engineered protein immuno-oncology (tumor-activated engagers, masked antibodies) aligns with durable industry tailwinds toward selective, tolerable therapies. Technical differentiation in safety and tumor specificity can create competitive advantage and partnership interest across multiple clinical stages.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow, with deterioration in TTM vs. 2025, reflects an ongoing cash burn profile. That structural outflow pressure forces reliance on external funding, shortens runway absent milestone receipts, and elevates dilution or financing risk over the coming quarters.
Large Operating LossesDeep operating losses and very negative net margins show the company is not yet generating scalable earnings from operations. Persistent negative returns (ROE roughly -12%) mean shareholder capital is being consumed, limiting reinvestment capacity and making long-term viability dependent on successful clinical outcomes or external funding.
Funding Reliance On Partners And EquityRevenue largely comes from collaborations and milestone payments, while operations are financed via equity raises. This structural funding model creates uneven revenue timing and dilution risk, constrains long-term planning, and ties program progress to partner decisions and capital market access.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $934.89M.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 16 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.161.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,984,352 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.33 (104.38% Upside)
$32.33 (104.38% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 289.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$32.33
▲(104.38% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
20.15% Insiders
13.19% Mutual Funds
0.30% Other Institutional Investors
53.71% Public Companies and
Individual Investors